The molecular pharmacology of glucagon agonists in diabetes and obesity
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The molecular pharmacology of glucagon agonists in diabetes and obesity
Authors
Keywords
-
Journal
PEPTIDES
Volume 165, Issue -, Pages 171003
Publisher
Elsevier BV
Online
2023-03-29
DOI
10.1016/j.peptides.2023.171003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Community Guidelines for GPCR Ligand Bias: IUPHAR Review XX
- (2022) Peter Kolb et al. BRITISH JOURNAL OF PHARMACOLOGY
- Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
- (2022) Fenghui Zhao et al. Nature Communications
- Glucagon, cyclic AMP, and hepatic glucose mobilization: A half‐century of uncertainty
- (2022) Robert L. Rodgers Physiological Reports
- Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes
- (2022) Anandan Palani et al. ACS Medicinal Chemistry Letters
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes
- (2022) Hongwei Jiang et al. Nature Communications
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
- (2022) Michael A. Nauck et al. Cardiovascular Diabetology
- Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes
- (2022) Revathi Sekar et al. Cell Metabolism
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
- (2022) Tamer Coskun et al. Cell Metabolism
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
- (2022) Shweta Urva et al. LANCET
- Glucagon receptor-mediated regulation of gluconeogenic gene transcription is endocytosis-dependent in primary hepatocytes
- (2022) Jan Mikhale B. Cajulao et al. MOLECULAR BIOLOGY OF THE CELL
- A novel glucagon analog with an extended half-life, HM15136, normalizes glucose levels in rodent models of congenital hyperinsulinism
- (2022) Yong Ho Heo et al. Scientific Reports
- Hepatocyte cholesterol content modulates glucagon receptor signalling
- (2022) Emma Rose McGlone et al. Molecular Metabolism
- Gut–hormone triple agonists: clinical safety and metabolic benefits
- (2022) Timo D Müller et al. LANCET
- Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins
- (2022) Ilana B. Kotliar et al. PHARMACOLOGICAL REVIEWS
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
- (2022) Linong Ji et al. EClinicalMedicine
- The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
- (2021) Qian Zhang et al. Cell Metabolism
- Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists
- (2021) Bin Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Effect of a Single Bout of Continuous Aerobic Exercise on Glucose, Insulin and Glucagon Concentrations Compared to Resting Conditions in Healthy Adults: A Systematic Review, Meta-Analysis and Meta-Regression
- (2021) James Frampton et al. SPORTS MEDICINE
- Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
- (2021) Phil Pickford et al. Molecular Metabolism
- Proglucagon-Derived Peptides as Therapeutics
- (2021) Ryan A. Lafferty et al. Frontiers in Endocrinology
- The hepatic glucose-mobilizing effect of glucagon is not mediated by cyclic AMP most of the time
- (2021) Robert L. Rodgers AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
- (2021) David C. D. Hope et al. Frontiers in Endocrinology
- Modulating effects of RAMPs on signaling profiles of the glucagon receptor family
- (2021) Lijun Shao et al. Acta Pharmaceutica Sinica B
- β-Arrestins as Important Regulators of Glucose and Energy Homeostasis
- (2021) Sai P. Pydi et al. Annual Review of Physiology
- Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
- (2021) Martin Bossart et al. Cell Metabolism
- A glucagon analogue decreases body weight in mice via signalling in the liver
- (2021) Charlotte E. Hinds et al. Scientific Reports
- Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling
- (2021) Emma Rose McGlone et al. Molecular Metabolism
- Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis
- (2020) Malte P. Suppli et al. DIABETES
- Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis
- (2020) Rachel J. Perry et al. NATURE
- Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice
- (2020) Ying Zhong et al. Oxidative Medicine and Cellular Longevity
- Glucagon receptor signaling is not required for N-carbamoyl glutamate- and l-citrulline-induced ureagenesis in mice
- (2020) Katrine D. Galsgaard et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Structural basis of Gs and Gi recognition by the human glucagon receptor
- (2020) Anna Qiao et al. SCIENCE
- Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes
- (2020) Muhmmad Omar-Hmeadi et al. Nature Communications
- Small molecule glucagon receptor antagonists: an updated patent review (2015–2019)
- (2020) Chen Cheng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors
- (2020) Sanaz Darbalaei et al. BIOCHEMICAL PHARMACOLOGY
- HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
- (2020) Manal Abdelmalek et al. JOURNAL OF HEPATOLOGY
- The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice
- (2020) Bo Ahrén et al. PEPTIDES
- Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
- (2020) Olof Eriksson et al. Scientific Reports
- Hepatokines and metabolism: Deciphering communication from the liver
- (2020) Sharon O. Jensen-Cody et al. Molecular Metabolism
- Mechanisms Influencing The Disposition Of Monoclonal Antibodies And Peptides
- (2019) Amita Datta-Mannan DRUG METABOLISM AND DISPOSITION
- Glucagon Receptor Signaling and Lipid Metabolism
- (2019) Katrine D. Galsgaard et al. Frontiers in Physiology
- The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice
- (2019) Jacqueline L. Beaudry et al. Molecular Metabolism
- Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
- (2019) Brian Finan et al. DIABETES
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells
- (2019) Teresa Buenaventura et al. PLOS BIOLOGY
- Multiplexed analysis of the secretin-like GPCR-RAMP interactome
- (2019) Emily Lorenzen et al. Science Advances
- Glucagon Regulation of Energy Expenditure
- (2019) Maximilian Kleinert et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Obesity dysregulates fasting-induced changes in glucagon secretion
- (2019) Jennifer H Stern et al. JOURNAL OF ENDOCRINOLOGY
- Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
- (2019) Patrick J. Knerr et al. PEPTIDES
- Dual glucagon‐like peptide‐1 receptor/glucagon receptor agonist SAR425899 improves beta‐cell function in type 2 diabetes
- (2019) Roberto Visentin et al. DIABETES OBESITY & METABOLISM
- MEDI0382, a GLP-1-glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomised, phase 1 study
- (2018) Philip D. Ambery et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Glucagon-receptor Signaling Regulates Energy Metabolism Via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21
- (2018) Teayoun Kim et al. DIABETES
- Amino Acid Metabolism Is Regulated by Glucagon Receptor Signaling in Mice
- (2018) MARIE WINTHER-SOERENSEN et al. DIABETES
- Hemodynamic Effects of Glucagon: A Literature Review
- (2018) Kasper Meidahl Petersen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
- (2018) R. Scott et al. PEPTIDES
- Single-Molecule Imaging of GPCR Interactions
- (2018) Davide Calebiro et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Targeting GLP-1 receptor trafficking to improve agonist efficacy
- (2018) Ben Jones et al. Nature Communications
- Hepatic Glucagon-Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents
- (2018) Teayoun Kim et al. DIABETES
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Peptide-based multi-agonists: a new paradigm in metabolic pharmacology
- (2018) Sara J. Brandt et al. JOURNAL OF INTERNAL MEDICINE
- Does glucagon have a positive inotropic effect in the human heart?
- (2018) Jesus Hernández-Cascales Cardiovascular Diabetology
- Membrane Lipid Nanodomains
- (2018) Marek Cebecauer et al. CHEMICAL REVIEWS
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling
- (2017) Jaimini Cegla et al. ENDOCRINOLOGY
- Hepatic β-arrestin 2 is essential for maintaining euglycemia
- (2017) Lu Zhu et al. JOURNAL OF CLINICAL INVESTIGATION
- Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
- (2017) Andreas Evers et al. JOURNAL OF MEDICINAL CHEMISTRY
- The New Biology and Pharmacology of Glucagon
- (2017) T. D. Müller et al. PHYSIOLOGICAL REVIEWS
- Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease
- (2016) Brian Finan et al. CELL
- Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
- (2016) Matthias H. Tschöp et al. Cell Metabolism
- Effects of 13-Hour Hyperglucagonemia on Energy Expenditure and Hepatic Glucose Production in Humans
- (2016) Manu Chakravarthy et al. DIABETES
- Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
- (2016) S. J. Henderson et al. DIABETES OBESITY & METABOLISM
- The β-Arrestins: Multifunctional Regulators of G Protein-coupled Receptors
- (2016) Jeffrey S. Smith et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B
- (2016) M. Johanns et al. Nature Communications
- Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
- (2015) Christof M. Kazda et al. DIABETES CARE
- Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes
- (2015) R. P. Kelly et al. DIABETES OBESITY & METABOLISM
- Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys
- (2015) Haruka Okamoto et al. ENDOCRINOLOGY
- Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2)
- (2015) Cathryn Weston et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Glucagon receptor antagonism induces increased cholesterol absorption
- (2015) Hong-Ping Guan et al. JOURNAL OF LIPID RESEARCH
- Glucagon Increases Beating Rate but Not Contractility in Rat Right Atrium. Comparison with Isoproterenol
- (2015) Beatriz Merino et al. PLoS One
- Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis
- (2015) Joseph P. Tiano et al. Scientific Reports
- Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction
- (2015) Safina Ali et al. Molecular Metabolism
- Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
- (2014) Jaimini Cegla et al. DIABETES
- A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation
- (2014) Aisling M. Lynch et al. DIABETOLOGIA
- First proof of pharmacology in humans of a novel glucagon receptor antisense drug
- (2014) Marloes G. J. van Dongen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis
- (2014) Nikoleta G Tsvetanova et al. Nature Chemical Biology
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Thyroid Hormone Regulation of Metabolism
- (2014) Rashmi Mullur et al. PHYSIOLOGICAL REVIEWS
- Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
- (2013) K. M. Habegger et al. DIABETES
- Glucose regulation of glucagon secretion
- (2013) Erik Gylfe et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala
- (2013) J A Parker et al. INTERNATIONAL JOURNAL OF OBESITY
- Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
- (2013) Russell A. Miller et al. NATURE
- Thyroid hormones and skeletal muscle—new insights and potential implications
- (2013) Domenico Salvatore et al. Nature Reviews Endocrinology
- Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
- (2012) T. M. Tan et al. DIABETES
- Targeted estrogen delivery reverses the metabolic syndrome
- (2012) Brian Finan et al. NATURE MEDICINE
- The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
- (2012) Jennifer R. Kosinski et al. Obesity
- Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
- (2011) Y. Lee et al. DIABETES
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- (2009) A. Pocai et al. DIABETES
- Cardiac hypertrophy and thyroid hormone signaling
- (2009) Wolfgang Dillmann HEART FAILURE REVIEWS
- Glucagon receptor mediates calcium signaling by coupling to Gαq/11and Gαi/oin HEK293 cells
- (2009) Yazhen Xu et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
- Persistent cAMP-Signals Triggered by Internalized G-Protein–Coupled Receptors
- (2009) Davide Calebiro et al. PLOS BIOLOGY
- Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
- (2008) Safina Ali et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Glucagon receptors
- (2008) F. Authier et al. CELLULAR AND MOLECULAR LIFE SCIENCES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started